XENE
$36.50+1.53%
Xenon Pharmaceuticals Inc.Stock · HealthcareRussell 2000 · 0.2% of IWMNasdaq Composite · 0.01% of ONEQRussell 3000 · 0.008% of IWV
XENE financial statements
The full income statement, balance sheet, and cash-flow statement for Xenon Pharmaceuticals Inc. (XENE), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 75.8M2024-09 76.2M2024-12 76.5M2025-03 76.7M2025-06 77.1M2025-09 77.3M2025-12 83.2M2026-03 96.7M2026-06 96.8M+27.8% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 7.50M | 0.00 | 0.00-100.0% | 9.43M-48.8% | 18.4M-42.7% | |
| 381M+36.3% | 279M+30.5% | 214M+54.5% | 139M+42.2% | 97.4M+53.5% | ||
| Research & development | 301M+43.0% | 210M+25.6% | 168M+58.4% | 106M+40.2% | 75.5M+49.4% | |
| Selling, general & administrative | 79.6M+15.6% | 68.9M+48.0% | 46.5M+41.9% | 32.8M+49.4% | 22.0M+69.7% | |
| General & administrative | 79.6M+15.6% | 68.9M+48.0% | 46.5M+41.9% | 32.8M+49.4% | 22.0M+69.7% | |
| Operating income | -373M-33.6% | -279M-30.5% | -214M-65.7% | -129M-63.5% | -79.0M-152.4% | |
| Interest & investment income | 26.8M-36.0% | 41.9M+51.9% | 27.6M+217.0% | 8.71M+1769.7% | 466K-79.6% | |
| Other non-operating income | 28.2M-31.1% | 40.9M+30.3% | 31.4M+706.8% | 3.89M+3602.9% | 105K-95.2% | |
| Gain (loss) on equity securities | — | — | — | — | -719K-18075.0% | |
| Pre-tax income | -345M-44.7% | -238M-30.5% | -183M-45.9% | -125M-58.8% | -78.9M-171.1% | |
| Income tax | 1.02M+124.8% | -4.09M-1300.3% | -292K-347.5% | 118K+2066.7% | -6.00K+97.7% | |
| -346M-47.6% | -234M-28.5% | -182M-45.5% | -125M-58.9% | -78.9M-173.5% | ||
| Net income to common | — | -234M-28.5% | -182M-46.0% | -125M-62.1% | -77.1M-175.2% | |
| -$4.36-44.9% | -$3.01-10.3% | -$2.73-32.5% | -$2.06-16.4% | -$1.77-118.5% | ||
| EPS (basic) | -$4.36-44.9% | -$3.01-10.3% | -$2.73-32.5% | -$2.06-16.4% | -$1.77-118.5% | |
| Weighted-avg shares (basic) | 79.3M+1.7% | 77.9M+16.5% | 66.9M+10.5% | 60.5M+38.8% | 43.6M+26.3% | |
| Weighted-avg shares (diluted) | 79.3M+1.7% | 77.9M+16.5% | 66.9M+10.5% | 60.5M+38.8% | 43.6M+26.3% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 561M-11.7% | 635M-1.5% | 645M+7.4% | 600M+7.4% | 559M+207.5% | ||
| Cash & equivalents | 199M+39.6% | 143M-4.0% | 149M+159.7% | 57.2M-67.4% | 176M+290.3% | |
| Short-term investments | 350M-27.8% | 484M-1.1% | 489M-8.5% | 535M+42.2% | 376M+184.9% | |
| Accounts receivable | — | 1.47M+68.1% | 874K-11.4% | 986K-64.3% | 2.77M+51.8% | |
| Prepaid expenses | 10.4M+50.8% | 6.89M+14.7% | 6.01M-16.9% | 7.22M+61.2% | 4.48M+51.2% | |
| 633M-20.7% | 798M-17.3% | 965M+27.9% | 754M+31.8% | 572M+202.4% | ||
| Property, plant & equipment | 8.72M-15.1% | 10.3M+6.5% | 9.65M+48.5% | 6.50M+45.5% | 4.47M+25.7% | |
| Operating lease right-of-use | 6.63M-16.5% | 7.94M-13.6% | 9.19M-11.7% | 10.4M+29.2% | 8.06M+142.2% | |
| Long-term investments | 37.2M-70.9% | 127M-56.5% | 293M+127.5% | 129M | 0.00 | |
| Deferred tax assets | 12.9M+33.1% | 9.67M+1105.2% | 802K+57.6% | 509K+9.5% | 465K-11.1% | |
| 41.8M+17.4% | 35.6M+30.5% | 27.3M+20.1% | 22.7M+58.5% | 14.3M-3.1% | ||
| Accounts payable | 3.88M-23.4% | 5.07M-41.0% | 8.60M+1.3% | 8.49M+122.0% | 3.82M+25.7% | |
| Accrued liabilities | 36.4M+6.3% | 34.2M+31.8% | 26.0M+16.9% | 22.2M+61.9% | 13.7M+26.1% | |
| Current lease liability | 1.53M+11.9% | 1.37M+5.4% | 1.30M+166.2% | 488K-19.3% | 605K+128.3% | |
| 51.4M+18.9% | 43.2M+17.2% | 36.9M+12.9% | 32.6M+48.6% | 22.0M+23.2% | ||
| Non-current lease liability | 6.41M-16.1% | 7.65M-20.4% | 9.60M-3.4% | 9.95M+30.0% | 7.65M+150.9% | |
| Operating lease liability (total) | 7.94M-11.9% | 9.02M-17.3% | 10.9M+4.5% | 10.4M+26.4% | 8.26M+149.1% | |
| Other non-current liabilities | 3.20M | 0.00 | — | — | — | |
| 582M-22.9% | 755M-18.6% | 928M+28.6% | 721M+31.2% | 550M+221.0% | ||
| Preferred stock | — | — | — | — | 7.73M+0.0% | |
| Common stock | 1.60B+9.7% | 1.46B+1.4% | 1.44B+34.9% | 1.07B+36.0% | 783M+96.9% | |
| Additional paid-in capital | 228M+14.6% | 199M+27.0% | 157M+10.3% | 142M+20.9% | 117M+159.0% | |
| Retained earnings | -1.25B-38.5% | -899M-35.2% | -665M-37.8% | -483M-35.1% | -357M-28.3% | |
| Accumulated other comprehensive income | 335K+120.8% | -1.61M-1993.5% | -77.0K+97.4% | -3.00M-203.0% | -990K+0.0% | |
| Total liabilities & equity | 633M-20.7% | 798M-17.3% | 965M+27.9% | 754M+31.8% | 572M+202.4% | |
| Common shares issued | 80.0M+4.7% | 76.4M+1.4% | 75.4M+20.4% | 62.6M+21.2% | 51.6M+47.5% | |
| Common shares outstanding | 80.0M+4.7% | 76.4M+1.4% | 75.4M+20.4% | 62.6M+21.2% | 51.6M+47.5% | |
| Shares outstanding (cover) | 83.2M+8.7% | 76.5M+1.5% | 75.4M+19.7% | 63.0M+21.4% | 51.9M+45.0% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -279M-53.9% | -181M-20.0% | -151M-49.6% | -101M-45.4% | -69.5M-44.4% | ||
| Depreciation & amortization | 2.54M-0.7% | 2.56M+24.2% | 2.06M+46.7% | 1.41M+55.1% | 906K+40.7% | |
| Share-based compensation | 53.7M+5.9% | 50.7M+56.7% | 32.4M+58.9% | 20.4M+103.4% | 10.0M+76.4% | |
| Deferred income taxes | -3.20M+63.9% | -8.86M-2935.6% | -292K-563.6% | -44.0K-175.9% | 58.0K+120.4% | |
| Change in receivables | — | 614K+572.3% | -130K+92.6% | -1.76M-482.8% | 459K-55.5% | |
| 218M+32.1% | 165M+248.1% | -111M+62.0% | -293M-18.9% | -247M-1366.8% | ||
| Capital expenditure | 799K-74.0% | 3.08M-45.3% | 5.62M+94.1% | 2.89M+41.2% | 2.05M-22.3% | |
| Free cash flow | -280M-51.7% | -184M-17.7% | -157M-50.8% | -104M-45.2% | -71.6M-41.0% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 117M+865.5% | 12.1M-96.6% | 354M+27.0% | 278M-37.8% | 448M+421.6% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 458K+127.4% | -1.67M-544.7% | 376K+115.1% | -2.48M-319.6% | -592K+0.2% | |
| Net change in cash | 56.5M+1051.8% | -5.93M-106.5% | 91.4M+177.2% | -118M-190.6% | 131M+545.2% | |
| Interest paid | — | — | — | 0.00 | 0.00-100.0% | |
| Income taxes paid | 8.42M | — | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 3.73B+24.3% | 3.00B-0.4% | 3.01B+22.2% | 2.47B+52.0% | 1.62B+194.5% | |
| P/S | 497.1× | — | 319.5×+70.6% | 187.2×+112.8% | 88.0×+413.8% | |
| P/B | 6.4×+61.3% | 4.0×-16.0% | 4.7×+44.6% | 3.3×+11.0% | 2.9×-8.2% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: XENE’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all XENE filings on SEC EDGAR → Not investment advice.